Work

Abstract LB012: Efficacy of atezolizumab in the treatment of solid tumors with high tumor mutational burden (TMB): A MyPathway study cohort

Year: 2021

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2021-lb012

Authors: John Hainsworth, Claire F. Friedman, Razelle Kurzrock, David R. Spigel, Howard Burris, Christopher J. Sweeney, Funda Meric-Bernstam, Yong Wang, Jonathan Levy, David Shames, Katja Schulze, Arisha Patel, Charles Swanton

Institutions: Sarah Cannon, Memorial Sloan Kettering Cancer Center, University of California San Diego, Harvard University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, The University of Texas MD Anderson Cancer Center, Instacart (United States), The Francis Crick Institute

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3177772694

Cites:

Cited by: 3

Related to: 10